Cardiac stem cell-derived exosomes have been demonstrated to promote cardiac regeneration following myocardial infarction in preclinical studies. Recent studies have used intramyocardial injection in order to concentrate exosomes in the infarct. Though effective in a research setting， this method is not clinically appealing due to its invasive nature. We propose the use of a targeting peptide， cardiac homing peptide (CHP)， to target intravenously-infused exosomes to the infarcted heart. Exosomes were conjugated with CHP through a DOPE-NHS linker. targeting was analyzed by incubating organ sections with the CHP exosomes and analyzing with fluorescence microscopy. assays were performed on neonatal rat ca... More
Cardiac stem cell-derived exosomes have been demonstrated to promote cardiac regeneration following myocardial infarction in preclinical studies. Recent studies have used intramyocardial injection in order to concentrate exosomes in the infarct. Though effective in a research setting， this method is not clinically appealing due to its invasive nature. We propose the use of a targeting peptide， cardiac homing peptide (CHP)， to target intravenously-infused exosomes to the infarcted heart. Exosomes were conjugated with CHP through a DOPE-NHS linker. targeting was analyzed by incubating organ sections with the CHP exosomes and analyzing with fluorescence microscopy. assays were performed on neonatal rat cardiomyocytes and H9C2 cells. For the animal study， we utilized an ischemia/reperfusion rat model. Animals were treated with either saline， scramble peptide exosomes， or CHP exosomes 24 h after surgery. Echocardiography was performed 4 h after surgery and 21 d after surgery. At 21 d， animals were sacrificed， and organs were collected for analysis. By conjugating the exosomes with CHP， we demonstrate increased retention of the exosomes within heart sections and with neonatal rat cardiomyocytes. studies showed improved viability， reduced apoptosis and increased exosome uptake when using CHP-XOs. Using an animal model of ischemia/reperfusion injury， we measured the heart function， infarct size， cellular proliferation， and angiogenesis， with improved outcomes with the CHP exosomes. Our results demonstrate a novel method for increasing delivery of for treatment of myocardial infarction. By targeting exosomes to the infarcted heart， there was a significant improvement in outcomes with reduced fibrosis and scar size， and increased cellular proliferation and angiogenesis.
